Table 1.
Demographic and delivery characteristics of pregnant women linked to live-born infants and actively treated with immunomodulatory agents 3-months prior to conception for selected rheumatologic conditions
| Medicaid enrollees (2000–2010) | United enrollees (2004–2012) | |||||||
|---|---|---|---|---|---|---|---|---|
| SLE (n=712) | RA (n=596) | PsA/AS (n=178) | SLE, RA, PsA or AS* (n=1,663) | SLE (n=285) | RA (n=394) | PsA/AS (n=185) | SLE, RA, PsA or AS* (n=982) | |
| Maternal age, years (Mean±SD) | 26.3 ± 5.8 | 28.1 ± 6.2 | 26.4 ± 5.1 | 27.1 ± 6.0 | 32.0 ± 5.3 | 32.5 ± 5.0 | 32.9 ± 4.8 | 32.4 ± 5.0 |
| Maternal race** | ||||||||
| White | 194 (27.2) | 270 (45.3) | 143 (80.3) | 672 (40.5) | - | - | - | - |
| Black | 321 (45.1) | 108 (18.1) | 13 (7.3) | 498 (29.9) | - | - | - | - |
| Hispanic | 140 (19.7) | 141 (23.7) | <11 | 328 (19.7) | - | - | - | - |
| Other | 57 (8.0) | 77 (12.9) | 13 (7.3) | 165 (9.9) | - | - | - | - |
| Region | ||||||||
| Midwest | 176 (24.7) | 161 (27.0) | 76 (42.7) | 466 (28.0) | 52 (18.5) | 93 (23.6) | 42 (22.7) | 207 (21.1) |
| Northeast | 157 (22.1) | 104 (17.4) | 27 (15.2) | 319 (19.2) | 40 (14.0) | 61 (15.5) | 18 (9.7) | 150 (15.3) |
| South | 226 (31.7) | 156 (26.2) | 58 (32.6) | 488 (29.3) | 132 (46.3) | 168 (42.6) | 94 (50.8) | 445 (45.3) |
| West | 153 (21.5) | 175 (29.4) | 17 (9.5) | 390 (23.5) | 61 (21.4) | 72 (18.3) | 31 (16.8) | 180 (18.3) |
*
Total number in the overall cohort is greater than the sum of three individual cohorts because the overall cohort includes women with recorded diagnoses of multiple conditions, who were excluded from individual cohorts.
**
Race information not recorded in United Healthcare claims.
Abbreviations: AS- Ankylosing spondylitis, PsA- Psoriatic arthritis, RA- Rheumatoid arthritis, SLE- Systematic lupus erythematosus